Anti-Müllerian Hormone and Inhibin B in the Definition of Ovarian Aging and the Menopause Transition

Sowers, MaryFran; Eyvazzadeh, Aimee D.; McConnell, Daniel S.; Yosef, Matheos; Jannausch, Mary; Zhang, Daowen; Harlow, Sioḃán D.; Randolph, John F.

doi:10.1097/01.ogx.0000345380.74110.a6

Cited by 22 publications

(28 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 Consequently, it is rapidly being adopted by clinicians in reproductive medicine to individualize stimulation strategies and improve outcome counselling for women about to undergo assisted conception. In addition, AMH has been proposed as a means to predict the age of menopause, 18 with further longitudinal studies ongoing.…”

Section: Introductionmentioning

confidence: 99%

A multicentre evaluation of the new Beckman Coulter anti-Müllerian hormone immunoassay (AMH Gen II)

Faye²,

et al. 2011

View full text Add to dashboard Cite

Background: The measurement of anti-Mü llerian hormone (AMH) has been by two commercial enzyme-linked immunosorbent (ELISA) assays: Diagnostics Systems Laboratory (DSL 10-14400) and Immunotech (A11893 IVD EU only). Beckman Coulter has developed a new assay for AMH (AMH Gen II A79765), which uses the DSL antibodies but is standardized to the Immunotech calibration. As a result, comparative data are urgently required between the old DSL assay and its replacement AMH Gen II. Methods: An evaluation of the AMH Gen II assay was performed at three sites, each with extensive experience of measuring circulating AMH in the adult female. Results were compared with the original DSL ELISA assay. The analysis was performed on a total of 271 patients' samples, approximately 90 at each site. Results: Performance characteristics were evaluated for the AMHGen II assay. Linearity was acceptable with observed values close to the expected (mean recovery 106.3%). The functional sensitivity (20% coefficient of variation), calculated from precision profile data, was 1.5 pmol/L. Within-and between-batch imprecision, assessed over the concentration range of 5 -70 pmol/L, were 5.3 -11.4% and 3.8 -17.3%, respectively. There was good agreement between assays with a Bablok-Passing regression equation AMH Gen II ¼ 1.40 DSL-0.62 pmol/L, r ¼ 0.96, n ¼ 271.Conclusions: Our results demonstrate that similar precision and excellent between-assay agreement should be obtained when laboratories change from the DSL to the AMH Gen II ELISA and they should expect an increase in AMH values of approximately 40%.

show abstract

Section: Introductionmentioning

confidence: 99%

A multicentre evaluation of the new Beckman Coulter anti-Müllerian hormone immunoassay (AMH Gen II)

Faye²,

et al. 2011

View full text Add to dashboard Cite

show abstract

“…This indicator of the ageing of the neuroendocrine system should be considered seriously, since this physiological process, the decrease in the estradiol and progesterone levels -in addition to the decrease in inhibin B and AMH levels and the increase in FSH levels -could help predict the end of the reproductive period and could warn women and their health care providers about the beginning of the body structural and functional changes associated with the menopausal transition. It must be emphasized that the increasing level of FSH and the decreasing level of estradiol are currently accepted as the major endocrine markers of the menopausal transition in the clinical practice [93,94]. Both early and the late onsets of reproductive ageing in women lead to serious health consequences.…”

Section: Discussionmentioning

confidence: 99%

Body fatness and endogenous sex hormones in the menopausal transition

et al. 2016

View full text Add to dashboard Cite

a b s t r a c tBackground: Age at the final menstrual period is of clinical and public health interest because the age at which natural menopause occurs may be a marker of ageing and health, and in general the menopausal transition increases the risk of many diseases, e.g. redistribution in the pattern of adiposity during the menopausal transition may increase risk of metabolic disease. The purpose of this research was to study the relationship between the menopausal status and body fatness. Subjects and methods: A random sample of 1932Hungarian women was studied. Body composition was estimated by body impedance analysis. In a subsample free estradiol and progesterone levels in saliva were quantified. Results: Body fat mass increased until the late 50s and then had a decrease through senescence. Premenopausal women who were much older than the median age at menopause had a higher amount of fat than their postmenopausal age-peers, while postmenopausal women, whose menopause occurred much earlier than the median age at menopause, had less fat than their premenopausal age-peers. The body fat mass in premenopausal women with low levels of sex hormones was always below the agemedian value of the menopausal status subgroups, while the body fat mass of postmenopausal women with high levels of sex hormone levels was above the age-median values. Conclusions: The analysis of body fatness in the menopausal transition revealed that (1) the rate of reproductive ageing and the body fat pattern were significantly related, and (2) body fat mass of women with unexpected levels of sex hormones was related more to their hormonal levels than to their menopausal status or their age. Thus future epidemiological screenings of women exposed to higher levels of menopause-related health risks should be expanded beyond the estimation of menopausal status based only on menstrual history to include sex hormone level assessment, as well as body composition analysis.

show abstract

“…Inhibin-B is a product of the smaller nondominant antral follicles and, as such, reflects the ovarian follicle pool (Hall et al 1999). Serum inhibin-B levels decrease to very low or undetectable levels about 4 years before the last menstrual period (Sowers et al 2008a). In longitudinal studies, inhibin-B correlates with age only during a relatively short time before menopausal transition (van Rooij et al 2005).…”

Section: Evaluating or In Cancer Patientsmentioning

confidence: 99%

Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer

Torino¹,

Barnabei²,

Vecchis³

et al. 2012

Endocrine-Related Cancer

View full text Add to dashboard Cite

Cytotoxic anticancer treatment may induce amenorrhea or menopause to a variable extent. These side effects may not only impair or impede fertility but also cause sexual dysfunction, bone loss, and menopausal symptoms, with a strikingly negative effect on quality of life in many women. Aromatase inhibitors (AIs) are a recommended adjuvant endocrine treatment option in postmenopausal patients affected by early breast cancer (EBC) but are contraindicated in premenopausal women and in those with residual ovarian function. Women over 40 years of age with chemotherapy-induced amenorrhea (CIA) and routine hormonal levels consistent with menopause may receive an AI as adjuvant endocrine treatment. For these women, the tools available to identify menopause do not appear to be completely reliable. This review focused on the pathophysiology of ovarian toxicity induced by cytotoxic agents and on potentially useful methods to diagnose chemotherapy-induced menopause in patients treated with adjuvant chemotherapy for endocrine-responsive EBC. Moreover, practical approaches are proposed to distinguish true menopausal women, who would benefit from AIs, from those with transient or persistent CIA.

show abstract

Anti-Müllerian Hormone and Inhibin B in the Definition of Ovarian Aging and the Menopause Transition

Cited by 22 publications

References 5 publications

A multicentre evaluation of the new Beckman Coulter anti-Müllerian hormone immunoassay (AMH Gen II)

A multicentre evaluation of the new Beckman Coulter anti-Müllerian hormone immunoassay (AMH Gen II)

Body fatness and endogenous sex hormones in the menopausal transition

Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer

Contact Info

Product

Resources

About